Literature DB >> 17510783

High-resolution analysis of CpG methylation and in vivo protein-DNA interactions at the alternative Epstein-Barr virus latency promoters Qp and Cp in the nasopharyngeal carcinoma cell line C666-1.

Agnes Bakos1, Ferenc Banati, Anita Koroknai, Maria Takacs, Daniel Salamon, Susanna Minarovits-Kormuta, Fritz Schwarzmann, Hans Wolf, Hans Helmut Niller, Janos Minarovits.   

Abstract

Transcripts for the Epstein-Barr virus (EBV) encoded nuclear antigens (EBNAs) are initiated at alternative promoters (Wp, Cp, for EBNA 1-6 transcripts and Qp, for EBNA 1 transcripts only) located in the BamHI W, C or Q fragment of the viral genome. To understand the host-cell dependent expression of EBNAs in EBV-associated tumors (lymphomas and carcinomas) and in vitro transformed cell lines, it is necessary to analyse the regulatory mechanisms governing the activity of the alternative promoters of EBNA transcripts. Such studies focused mainly on lymphoid cell lines carrying latent EBV genomes, due to the lack of EBV-associated carcinoma cell lines maintaining latent EBV genomes during cultivation in tissue culture. We took advantage of the unique nasopharyngeal carcinoma cell line, C666-1, harboring EBV genomes, and undertook a detailed analysis of CpG methylation patterns and in vivo protein-DNA interactions at the latency promoters Qp and Cp. We found that the active, unmethylated Qp was marked with strong footprints of cellular transcription factors and the viral protein EBNA 1. In contrast, we could not detect binding of relevant transcription factors to the methylated, silent Cp. We concluded that the epigenetic marks at Qp and Cp in C666-1 cells of epithelial origin resemble those of group I Burkitt's lymphoma cell lines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510783     DOI: 10.1007/s11262-007-0095-y

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  29 in total

1.  Interferon regulatory factor 2 represses the Epstein-Barr virus BamHI Q latency promoter in type III latency.

Authors:  L Zhang; J S Pagano
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

2.  Nucleoprotein structure of immediate-early promoters Zp and Rp and of oriLyt of latent Epstein-Barr virus genomes.

Authors:  Hans Helmut Niller; Daniel Salamon; Jörg Uhlig; Stefanie Ranf; Marcus Granz; Fritz Schwarzmann; Hans Wolf; Janos Minarovits
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 3.  Epigenetic regulation of lymphoid specific gene sets.

Authors:  Ildikó Györy; Janos Minarovits
Journal:  Biochem Cell Biol       Date:  2005-06       Impact factor: 3.626

Review 4.  Epigenotypes of latent herpesvirus genomes.

Authors:  J Minarovits
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

5.  The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive.

Authors:  Q Tao; K D Robertson; A Manns; A Hildesheim; R F Ambinder
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

6.  Detection of transcripts initiated from two viral promoters (Cp and Wp) in Epstein-Barr virus-infected nasopharyngeal carcinoma cells and biopsies.

Authors:  Y Chang; T S Sheen; J Lu; Y T Huang; J Y Chen; C S Yang; C H Tsai
Journal:  Lab Invest       Date:  1998-06       Impact factor: 5.662

7.  EB viral genomes in epithelial nasopharyngeal carcinoma cells.

Authors:  H Wolf; H zur Hausen; V Becker
Journal:  Nat New Biol       Date:  1973-08-22

8.  Nucleoprotein complexes and DNA 5'-ends at oriP of Epstein-Barr virus.

Authors:  H H Niller; G Glaser; R Knüchel; H Wolf
Journal:  J Biol Chem       Date:  1995-05-26       Impact factor: 5.157

9.  Repression of Epstein-Barr virus EBNA-1 gene transcription by pRb during restricted latency.

Authors:  I K Ruf; J Sample
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

10.  Automated fluorescent genomic sequencing as applied to the methylation analysis of the human ornithine decarboxylase gene.

Authors:  S Myöhänen; J Wahlfors; J Jänne
Journal:  DNA Seq       Date:  1994
View more
  7 in total

1.  Kank1 reexpression induced by 5-Aza-2'-deoxycytidine suppresses nasopharyngeal carcinoma cell proliferation and promotes apoptosis.

Authors:  Fan-Yan Luo; Shan Xiao; Zi-Hou Liu; Peng-Fei Zhang; Zhi-Qiang Xiao; Can-E Tang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 2.  Epigenetics and Genetics of Viral Latency.

Authors:  Paul M Lieberman
Journal:  Cell Host Microbe       Date:  2016-05-11       Impact factor: 21.023

Review 3.  Epigenetic regulation of EBV persistence and oncogenesis.

Authors:  Italo Tempera; Paul M Lieberman
Journal:  Semin Cancer Biol       Date:  2014-01-24       Impact factor: 15.707

4.  Acetylated histone H3 and H4 mark the upregulated LMP2A promoter of Epstein-Barr virus in lymphoid cells.

Authors:  Borbala Gerle; Anita Koroknai; György Fejer; Agnes Bakos; Ferenc Banati; Kalman Szenthe; Hans Wolf; Hans Helmut Niller; Janos Minarovits; Daniel Salamon
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

Review 5.  Epigenetic regulation of EBV and KSHV latency.

Authors:  Horng-Shen Chen; Fang Lu; Paul M Lieberman
Journal:  Curr Opin Virol       Date:  2013-04-16       Impact factor: 7.090

6.  RNA polymerase II stalling promotes nucleosome occlusion and pTEFb recruitment to drive immortalization by Epstein-Barr virus.

Authors:  Richard D Palermo; Helen M Webb; Michelle J West
Journal:  PLoS Pathog       Date:  2011-10-27       Impact factor: 6.823

7.  The B cell transcription program mediates hypomethylation and overexpression of key genes in Epstein-Barr virus-associated proliferative conversion.

Authors:  Henar Hernando; Claire Shannon-Lowe; Abul B Islam; Fatima Al-Shahrour; Javier Rodríguez-Ubreva; Virginia C Rodríguez-Cortez; Biola M Javierre; Cristina Mangas; Agustín F Fernández; Maribel Parra; Henri-Jacques Delecluse; Manel Esteller; Eduardo López-Granados; Mario F Fraga; Nuria López-Bigas; Esteban Ballestar
Journal:  Genome Biol       Date:  2013-01-15       Impact factor: 13.583

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.